Financial Performance - The company achieved revenue of RMB 18,871.3 million for the six months ended June 30, 2023, representing a year-on-year growth of 6.3%[4] - Net profit attributable to the parent company was RMB 5,313.1 million, an increase of 14.6% compared to the same period in 2022[4] - The adjusted net profit attributable to the parent company was RMB 5,094.7 million, reflecting an 18.5% year-on-year growth[4] - The company achieved a gross profit of RMB 7.56 billion, representing a year-on-year increase of 17.6%, with a gross margin of 40.0%[15] - The total comprehensive income for the period was RMB 4,843,228 thousand, compared to RMB 4,377,071 thousand in the same period of 2022, reflecting an increase of approximately 10.6%[90] - The company reported a significant increase in tax payable to RMB 819.1 million, up 58.2% due to increased taxable profits from subsidiaries during the reporting period[34] - The company reported a significant increase in accounts receivable and other receivables, which rose to RMB 9,237,398 thousand from RMB 7,590,361 thousand, reflecting an increase of about 21.7%[91] Revenue Breakdown - Revenue from U.S. clients reached RMB 12.37 billion, a 42% increase year-on-year when excluding COVID-19 commercialization projects[4] - Revenue from the top 20 global pharmaceutical companies was RMB 7.14 billion, showing a strong growth of 47% when excluding COVID-19 commercialization projects[5] - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year[6] - The WuXi Testing segment reported revenue of RMB 3,091.0 million, reflecting an 18.7% year-on-year growth[8] - The TIDES business revenue reached RMB 1.33 billion, with a year-on-year growth of 37.9%[7] - Clinical CRO and SMO achieved revenue of RMB 850 million, a year-on-year increase of 18.3%, with SMO business revenue growing by 34.3%[9] - The biology segment generated revenue of RMB 1.23 billion, reflecting a year-on-year growth of 13.0%, with new molecular-related revenue increasing by 51%[10] Client Growth and Market Presence - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months[4] - The company’s services to the top 20 global pharmaceutical companies accounted for approximately 38% of total revenue during the reporting period[47] - The early discovery platform contributed over 20% of new customers in the first half of 2023, serving over 1,600 clients with a compound library exceeding 90 billion molecules[10] Financial Position and Cash Flow - Net cash generated from operating activities was RMB 5,340.7 million for the six months ended June 30, 2023, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022[23] - Net cash used in investing activities decreased by 65.3% to RMB 1,307.8 million for the six months ended June 30, 2023, primarily due to timing differences in capital expenditures[24] - Total liabilities as of June 30, 2023, were RMB 19,120.4 million, up from RMB 17,763.7 million as of December 31, 2022[25] - The company's total borrowings amounted to RMB 4,422.1 million as of June 30, 2023, all of which were fixed-rate borrowings[26] - The debt-to-asset ratio as of June 30, 2023, was 27.6%, compared to 27.5% as of December 31, 2022, indicating a stable and healthy financial position[27] Strategic Investments and R&D - The company is preparing for the commercialization of CAR-T products, with production expected to start in the first half of 2024[11] - The company aims to enhance its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and peptide drugs, to seize new business opportunities[44] - The company is committed to continuous investment in global capabilities and scale to empower pharmaceutical innovation[43] - The company continues to focus on research and development in small molecule drugs, cell therapy, and gene therapy, positioning itself for future growth in these sectors[93] Risks and Challenges - The company recognizes potential risks from declining demand in the pharmaceutical R&D service market, which could negatively impact business if outsourcing trends slow down[70] - The pharmaceutical R&D service industry is highly regulated, with potential adverse impacts on the company's operations if it fails to adapt to changes in industry policies and regulations[71] - The global pharmaceutical R&D service market is becoming increasingly competitive, with threats from both established players and new entrants that may possess stronger financial and technical capabilities[72] - The company's main business revenue is primarily denominated in USD, exposing it to risks from significant appreciation of the RMB, which could increase costs and reduce order volumes[78] Shareholder Information - A total of 131,328 restricted A-shares were released from restrictions under the 2018 A-share incentive plan, accounting for approximately 0.005% of the company's total issued A-shares[49] - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares for shareholders listed on June 13, 2023[52] - The company completed the redemption of all outstanding zero-coupon convertible bonds amounting to $300 million on April 4, 2023[59] - The board did not recommend any interim dividend for the reporting period[82] Operational Enhancements - The company expanded its testing laboratory by 55,000 square meters during the reporting period, enhancing its capabilities and capacity[46] - The company is focused on enhancing its product offerings through continuous innovation and development of new technologies[132] - The company will maintain the highest international quality standards and continuously improve operational processes to ensure compliance and prevent accidents[66]

Financial Performance - The company's revenue for Q1 2023 was approximately ¥8.96 billion, representing a year-on-year increase of 5.77%[7] - Net profit attributable to shareholders for Q1 2023 was approximately ¥2.17 billion, reflecting a significant increase of 31.97% compared to the same period last year[7] - The net cash flow from operating activities reached approximately ¥3.03 billion, showing a remarkable increase of 508.55% year-on-year[7] - Total revenue for Q1 2023 reached ¥8,963,741,607.53, an increase of 5.8% compared to ¥8,474,419,333.59 in Q1 2022[28] - Operating profit for Q1 2023 was ¥2,615,354,834.65, up from ¥2,004,959,729.24 in Q1 2022, reflecting a growth of 30.5%[28] - Net profit for Q1 2023 was ¥2,185,804,643.61, compared to ¥1,655,950,521.89 in Q1 2022, representing a year-over-year increase of 31.9%[28] - The gross profit for Q1 2023 was ¥3,525,642,000, up from ¥3,014,848,000 in Q1 2022, which is an increase of approximately 17.0%[35] Assets and Liabilities - The total assets as of March 31, 2023, amounted to approximately ¥68.19 billion, an increase of 5.41% from the end of the previous year[8] - Total assets as of March 31, 2023, amounted to CNY 68,188,089 thousand, up from CNY 64,690,327 thousand at the end of 2022, indicating a growth of approximately 7%[38] - Total liabilities reached ¥18,357,086,099.46 as of March 31, 2023, compared to ¥17,763,654,011.21 at the end of 2022, showing an increase of 3.3%[26] - The total liabilities increased to CNY 18,357,086 thousand in Q1 2023 from CNY 17,763,654 thousand in Q4 2022, marking an increase of about 3.34%[39] - The company's equity attributable to shareholders increased to ¥49.47 billion, up by 6.19% compared to the end of the previous year[8] - The company's equity attributable to shareholders increased to CNY 49,474,883 thousand in Q1 2023 from CNY 46,589,953 thousand in Q4 2022, representing a growth of about 6%[39] Client and Market Activity - The company served over 6,000 active clients from more than 30 countries through its 32 operational bases as of the end of the reporting period[5] - The company added over 310 new clients, bringing the total active client count to over 6,000, indicating a sustained demand for services globally[12] - Revenue from existing clients accounted for 99% of total revenue, amounting to RMB 88.8 billion, a 7% increase year-on-year[12] - The company’s revenue from global top 20 pharmaceutical companies was RMB 31.5 billion, a 17% decline year-on-year, primarily due to project fluctuations[12] Business Segments Performance - The chemical business (WuXi Chemistry) generated RMB 643,278.20 million in revenue, up 5.1% year-on-year, with a 21.8% growth rate when excluding specific commercial projects[15][16] - The testing business (WuXi Testing) reported revenue of RMB 145,287.67 million, a 13.6% increase year-on-year, with laboratory analysis and testing services growing by 15.9%[16] - The biological business (WuXi Biology) achieved revenue of RMB 57,699.75 million, reflecting an 8.3% year-on-year growth, with new molecular-related services growing by 40%[17][18] - The CTDMO business (WuXi ATU) generated RMB 32,448.54 million, a year-on-year increase of 8.7%, with the cell and gene therapy testing business growing by 8.6%[18] Future Outlook - The company anticipates a revenue growth of 5-7% for the entire year of 2023, based on current order status and stable global pharmaceutical industry conditions[19] - Future revenue growth is expected to come primarily from drug sales revenue sharing, with a projected compound annual growth rate of around 50% over the next decade as more DDSU client drugs reach the market[19] Research and Development - Research and development expenses increased to ¥357,301,004.44 in Q1 2023, up from ¥280,042,477.39 in Q1 2022, marking a rise of 27.6%[28] - The company completed 3 IND applications and received 6 clinical trial approvals (CTA) in Q1 2023, with a total of 175 IND applications and 150 CTAs completed to date[19] - The company is working on 15 new molecular projects, including peptide-drug conjugates and oligonucleotides, with several IND applications expected to be submitted this year[19]

Financial Performance - The company reported a total revenue of RMB 8,963,741,607.53 for Q1 2023, representing a year-on-year increase of 5.77%[6] - Net profit attributable to shareholders reached RMB 2,168,128,379.15, marking a significant increase of 31.97% compared to the previous year[6] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 1,868,816,896.68, reflecting a 9.02% increase year-on-year[6] - Basic earnings per share were RMB 0.74, up by 32.14% year-on-year, while diluted earnings per share were RMB 0.72, increasing by 35.85%[6] - Total comprehensive income for Q1 2023 was RMB 2.17 billion, up from RMB 1.65 billion in Q1 2022, marking a 31.6% increase[28] - Net profit for Q1 2023 was RMB 2.19 billion, up 31.8% from RMB 1.66 billion in Q1 2022[27] - Operating profit for Q1 2023 was RMB 2.62 billion, compared to RMB 2.00 billion in Q1 2022, reflecting a 30.6% increase[26] - The company reported a net profit of 2,168,129 thousand RMB for Q1 2023, compared to 1,642,947 thousand RMB in Q1 2022, which is an increase of about 32%[38] Cash Flow and Assets - The net cash flow from operating activities surged to RMB 3,027,329,258.18, an impressive increase of 508.55% compared to the same period last year[6] - Cash flow from operating activities for Q1 2023 was RMB 3.03 billion, significantly higher than RMB 497.47 million in Q1 2022[30] - The company incurred a net cash outflow from investing activities of RMB 1,222,881,147.89 in Q1 2023, contrasting with a net inflow of RMB 1,474,723,859.12 in Q1 2022[31] - The company’s financing activities generated a net cash inflow of RMB 148,902,292.20 in Q1 2023, down from RMB 387,302,550.67 in Q1 2022[31] - The company’s cash and cash equivalents increased to RMB 9,867,844,029.10 by the end of Q1 2023, up from RMB 7,983,904,283.09 at the beginning of the quarter[34] - The company's cash and cash equivalents increased to 9,867,844 thousand RMB by the end of Q1 2023, compared to 7,026,525 thousand RMB at the end of Q1 2022, marking a growth of about 40%[37] Revenue Breakdown - Revenue from the chemical business reached RMB 6,432.8 million, a 5.1% increase compared to RMB 6,118.0 million in the same period last year[12] - The testing business generated revenue of RMB 1,452.9 million, reflecting a year-on-year growth of 13.6%[13] - The biology business achieved revenue of RMB 577.0 million, an increase of 8.3% compared to RMB 532.6 million in the same period of 2022[14] - The cell and gene therapy CTDMO business generated revenue of RMB 324.5 million, up 8.7% from RMB 298.6 million year-over-year[15] - Revenue from U.S. customers was RMB 5.41 billion, a 3% increase year-on-year, and a 22% increase when excluding COVID-19 commercialization projects[10] - Revenue from European customers grew by 19% year-on-year, reaching RMB 1.44 billion[10] Assets and Liabilities - Total assets as of March 31, 2023, amounted to RMB 68,188,088,624.62, a 5.41% increase from the end of the previous year[6] - The total liabilities as of March 31, 2023, were ¥18,357,086,099.46, compared to ¥17,763,654,011.21 at the end of 2022, representing a rise of approximately 3.3%[24] - The total current liabilities rose from 14,499,361 thousand RMB as of December 31, 2022, to 15,786,216 thousand RMB as of March 31, 2023, indicating an increase of approximately 8.87%[35] - The total equity attributable to shareholders increased to ¥49,474,882,627.12 from ¥46,589,953,393.31, showing a growth of approximately 6.3%[25] Business Operations and Strategy - The company serves over 6,000 active clients from more than 30 countries through 32 operational bases globally[4] - The workforce consists of 43,800 employees, with 13,147 holding master's degrees or higher, and 1,426 holding doctoral degrees[4] - The company continues to focus on talent retention through recruitment, training, and promotion to maintain high service standards and industry leadership[5] - The company added over 310 new customers in Q1 2023, bringing the total active customer count to over 6,000[10] - The company expects a revenue growth of 5-7% for the full year of 2023, based on current order status[17] - The company has completed IND applications for 175 projects and obtained CTA approvals for 150 projects as of the end of Q1 2023[16] - The company has developed a new drug for treating COVID-19, which has been approved for market launch in March 2023[16] - The company anticipates achieving approximately 50% compound growth rate in revenue from drug sales sharing agreements over the next decade[16] Research and Development - R&D expenses increased to RMB 357.30 million in Q1 2023, up from RMB 280.04 million in Q1 2022, representing a 27.6% rise[26] - The company has delivered over 260 ADC drug projects, establishing a comprehensive capability platform from early discovery to preclinical efficacy research[14] - The company is supporting 68 projects in the CTDMO service platform, including 52 preclinical and clinical phase I projects[15] - The new molecular-related revenue in the biology segment grew strongly by 40%, accounting for 25.3% of the total biology business revenue[14]

Financial Performance - In 2022, WuXi AppTec achieved a record revenue growth of 71.8% year-on-year, with total revenue reaching RMB 39,354.8 million compared to RMB 22,902.4 million in 2021[13]. - The adjusted net profit attributable to the parent company increased by 83.2% year-on-year, amounting to RMB 9,399.3 million, up from RMB 5,131.3 million in 2021[13]. - The gross profit margin improved to 36.9% in 2022, compared to 36.1% in the previous year[15]. - The company reported a net profit margin of 22.4% for the parent company, slightly up from 22.3% in 2021[15]. - The company achieved a revenue of RMB 39,354.8 million, representing a year-on-year growth of 71.8%[16]. - The net profit attributable to shareholders reached RMB 8,813.7 million, with a year-on-year increase of 72.9%[16]. - The company reported a net profit of RMB 8,902.6 million for 2022, a 73.3% increase from 2021, with a net profit margin rising from 22.4% to 22.6%[40]. - The company achieved a gross profit of RMB 14,506.5 million in 2022, an increase of 75.5% compared to the same period in 2021, with a main business gross profit of RMB 14,490.8 million and other business gross profit of RMB 15.7 million[26]. - The gross profit margin for the main business was 36.9%, up 0.8 percentage points from 2021[26]. Business Growth and Client Acquisition - WuXi AppTec's CRDMO and CTDMO business models continue to drive growth and meet increasing global customer demands[13]. - The company added over 1,400 new clients, serving more than 5,950 active clients from over 30 countries[16]. - Revenue from US clients was RMB 25,884 million, up 113% year-on-year; revenue from Chinese clients was RMB 7,526 million, up 30%[16]. - The chemical business (WuXi Chemistry) generated RMB 28,849.7 million, a 104.8% increase from RMB 14,087.2 million in 2021[18]. - The TIDES business saw a revenue increase of 337%, reaching RMB 1,578 million, with the number of service molecules growing by 91%[20]. Financial Stability and Assets - Total assets increased to RMB 64,690.3 million in 2022, up from RMB 55,127.4 million in 2021[15]. - The company maintained a debt-to-asset ratio of 27.5%, down from 29.7% in the previous year, indicating improved financial stability[15]. - The company’s cash and cash equivalents stood at RMB 7,983.9 million, compared to RMB 8,175.3 million in 2021[15]. - Total liabilities as of December 31, 2022, were RMB 17,763.7 million, an increase from RMB 16,369.9 million in 2021, with 40.8% attributed to accounts payable and other payables[43]. Research and Development - The company’s R&D expenses rose to RMB 1,614.0 million, a 71.3% increase from 2021, focusing on new molecular types such as PROTAC and gene therapy[35]. - The company aims to enhance its service capabilities for new molecular types such as PROTAC, oligonucleotide drugs, peptide drugs, and gene therapy, capturing new business opportunities[98]. Sustainability and ESG Commitment - The company emphasized its commitment to ESG principles, integrating them into all aspects of its operations[13]. - The company received silver certification from EcoVadis for sustainability ratings across its three bases in Changzhou, Shanghai, and Wuxi[20]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[120]. Future Outlook and Guidance - For 2023, WuXi Chemistry expects revenue growth of 36-38%, while other segments anticipate a 20-23% increase, with WuXi DDSU projected to decline over 20%[24]. - The company is confident in its future development and maintaining its industry-leading position[13]. - The company expects adjusted non-IFRS gross profit to grow by 12-14% in 2023, contributing to the growth of adjusted non-IFRS profit attributable to equity holders[52]. Corporate Governance and Management - The management team possesses extensive industry experience and a strong international perspective, enabling the company to quickly adapt to market trends and client needs[73]. - The company has established a robust internal control system to ensure compliance with laws and regulations, but risks remain due to the complexity of managing multiple subsidiaries[104]. - The board consists of 13 members, including 6 executive directors, ensuring diverse leadership and strategic oversight[113]. Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could negatively impact business if industry trends slow down[101]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, requiring the company to adapt its strategies to comply with evolving policies[102]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to strengthen its R&D capabilities[103]. Shareholder Communication and Dividends - The company has established a shareholder communication policy to ensure proper responses to shareholder concerns and feedback[172]. - The company proposed a cash dividend of RMB 8.9266 per 10 shares for the year 2022, totaling RMB 2,644,137,750.80, compared to RMB 1,529,441,704.14 in 2021[176].

证券代码：603259 证券简称：药明康德 公告编号：临 2023-026 无锡药明康德新药开发股份有限公司 关于召开 2022 年度业绩说明会的公告 （一）会议召开时间：2023 年 4 月 13 日（星期四）上午 10:30-11:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2023 年 3 月 21 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2022 年年度报告》。为了便于广大投资者更全面深入地 了解本公司 2022 年度业绩和经营情况，本公司拟于 2023 年 4 月 13 日（星期四） 上午 10:30-11:30 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2022 年度业 绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍关注 的问题进行回答。 二、业绩说明会召开的时 ...

Financial Performance - The company achieved a record revenue of RMB 39,354,777,805.53 in 2022, representing a growth of 71.84% compared to 2021[20]. - Net profit attributable to shareholders reached RMB 8,813,713,033.51, marking a 72.91% increase from the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 8,260,289,685.19, which is a 103.27% increase year-over-year[20]. - The net cash flow from operating activities was RMB 10,616,029,916.68, reflecting a significant increase of 131.32% compared to 2021[20]. - The company's total assets at the end of 2022 were RMB 64,690,326,746.96, up 17.35% from the previous year[20]. - Basic earnings per share for 2022 were RMB 3.01, an increase of 72.00% compared to 2021[21]. - The weighted average return on net assets was 20.62%, an increase of 6.57 percentage points from the previous year[21]. - The net profit attributable to shareholders increased by 72.91% year-on-year, while the net profit excluding non-recurring gains and losses grew by 103.27%[23]. - The net cash flow from operating activities reached RMB 1,061,602.99 million, a 131.32% increase compared to the same period in 2021[23]. - Basic earnings per share increased by 72.00%, diluted earnings per share rose by 63.01%, and basic earnings per share excluding non-recurring gains and losses grew by 102.88%[23]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 for the year 2022[4]. - There are no significant changes in the total share capital prior to the dividend distribution date[4]. - The net profit attributable to ordinary shareholders of the listed company for the consolidated financial statements is RMB 8,813,713,033.51, with a dividend payout ratio of 30%[144]. - The profit distribution plan has been approved by all directors, including independent non-executive directors, and will be submitted for approval at the annual general meeting[142]. Operational Risks and Compliance - The company has confirmed that there are no significant risks that could materially affect its operations during the reporting period[6]. - The company has outlined potential risks in its operations, which are detailed in the report[6]. - The company has not faced any violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any forward-looking commitments that could be construed as guarantees to investors[5]. - The company emphasizes compliance and has established a robust internal control system, but risks remain if oversight of subsidiaries is insufficient[94]. - The company faces risks from a potential decline in demand for pharmaceutical research services, which could negatively impact business if industry growth slows or outsourcing ratios decrease[91]. - Regulatory changes in the pharmaceutical research services industry could pose risks if the company fails to adapt its operational strategies to comply with new policies and regulations[92]. Business Growth and Customer Base - In 2022, the company added over 1,400 new customers, with active customers exceeding 5,950[31]. - Revenue from U.S. customers was RMB 25.884 billion, a 113% year-on-year increase; revenue from Chinese customers was RMB 7.526 billion, up 30%[31]. - Revenue from the top 20 global pharmaceutical companies reached RMB 18.421 billion, a 174% increase year-on-year[31]. - Revenue from existing customers amounted to RMB 37.781 billion, reflecting a 77% growth compared to the previous year[31]. - The company achieved a total revenue of RMB 36.736 billion from clients using multiple business units, marking an 87% increase[31]. Research and Development - R&D expenses increased by 71.29% to RMB 1,613,953,441.33, reflecting the company's commitment to innovation[48]. - The company is committed to advancing digital transformation and optimizing data utilization across various business departments[89]. - The company plans to strengthen its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, leveraging cutting-edge technologies[88]. - The company is focused on expanding its market presence and enhancing its research and development capabilities[125]. Environmental Management - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit by environmental protection authorities[156]. - The total SO₂ emissions from the company were 0.162 tons, with a concentration of 1.0 mg/m³, well below the standard limit of 200 mg/m³[157]. - The total NOx emissions were 6.30 tons, with a concentration of 49.9 mg/m³, also below the standard limit of 200 mg/m³[157]. - The company has implemented a waste management program to supervise and manage the generation, collection, classification, labeling, recording, storage, transportation, and disposal of waste[169]. - The company has established partnerships with qualified waste disposal units for the safe handling of hazardous waste, including animal carcasses and contaminated materials[183]. Governance and Management - The board of directors and management have ensured the accuracy and completeness of the annual report[2]. - The company has a complete business system and operates independently from the actual controller, with no business dependencies or competition[102]. - The board of directors includes a diverse group of experienced professionals, ensuring robust governance and strategic oversight[107]. - The company has maintained a consistent governance structure with independent directors overseeing key decisions[119]. - The total pre-tax remuneration for the Chairman and CEO, Ge Li, was CNY 41.97 million in the reporting period[104]. Future Outlook - The company expects a revenue growth of 5-7% in 2023, with WuXi Chemistry projected to grow by 36-38% and other business segments expected to grow by 20-23%[45]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach $1.875 billion[109]. - New product launches are expected to contribute an additional $300 million in revenue, with a focus on innovative solutions in the biotech sector[109]. - The company is exploring potential acquisitions to bolster its portfolio, with a budget of $500 million allocated for strategic investments[109].

Financial Performance - The company achieved a revenue of RMB 39,354.8 million for the year ended December 31, 2022, representing a year-on-year growth of 71.8%[4]. - The net profit attributable to shareholders was RMB 8,813.7 million, an increase of 72.9% compared to the previous year[4]. - The gross profit reached RMB 14,506.5 million, with a gross margin of 36.9%, slightly up from 36.1% in 2021[2]. - The adjusted net profit attributable to shareholders was RMB 9,399.3 million, marking an 83.2% increase from the previous year[2]. - The net profit for the year increased by 73.3% to RMB 8,902.6 million, with a net profit margin of 22.6%[28]. - Overall gross profit for the company increased by 75.5% to RMB 14,506.5 million in 2022, with a gross margin of 36.9%[16]. - The total comprehensive income for the year was RMB 9,195,719 thousand, compared to RMB 4,625,059 thousand in the previous year, indicating a growth of approximately 98%[116]. - The company reported a pre-tax profit of RMB 10,618,477 thousand for the year ended December 31, 2022[124]. - The total revenue for the year ended December 31, 2022, was RMB 39,354,778 thousand, representing an increase from RMB 22,902,385 thousand in the previous year, which is a growth of approximately 72%[115]. Revenue Breakdown - Revenue from US clients was RMB 25,884 million, a significant increase of 113% year-on-year[5]. - Revenue from new clients amounted to RMB 1,573 million, contributing to a total revenue from existing clients of RMB 37,781 million, which grew by 77%[5]. - The chemical business segment generated RMB 28,849.7 million, reflecting a remarkable growth of 104.8% year-on-year[7]. - The revenue from the top 20 global pharmaceutical companies was RMB 18,421 million, showing a substantial growth of 174% year-on-year[5]. - The TIDES business achieved a revenue of RMB 1.578 billion, representing a year-on-year growth of 337%, with the number of service molecules increasing by 91% to 189[9]. - The testing business generated revenue of RMB 5.719 billion, a 26.4% increase from RMB 4.525 billion in the same period last year, with laboratory analysis and testing services growing by 36.1%[10]. - The biology segment reported revenue of RMB 2.475 billion, up 24.7% from RMB 1.985 billion, with new molecular-related services growing by 90%[11]. - The cell and gene therapy CTDMO business achieved revenue of RMB 1.308 billion, a 27.4% increase from RMB 1.026 billion, with testing services growing by 36%[12]. Client and Market Expansion - The company added over 1,400 new clients, serving more than 5,950 active clients globally across 30 countries[4]. - The company is expanding its international presence with new bases planned in Singapore and a production facility underway in Middletown, Delaware, USA[62]. - The company hosted 7 online events during the reporting period, with a total registration of over 28,000 participants, including industry leaders and patients, focusing on major challenges and opportunities in the industry[63]. - The company completed 77 live broadcasts covering all five major business segments, reaching over 220,000 views across more than 20 countries and regions, including all 34 provincial-level administrative regions in China[63]. Investment and R&D - Research and development expenses rose by 71.3% to RMB 1,614.0 million in 2022, reflecting increased investment in new molecular types[23]. - The company plans to invest heavily in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, aiming to enhance its service capabilities and seize new business opportunities[89]. - The company has established a comprehensive "end-to-end" drug development service platform, benefiting from the rapid growth of the global drug development outsourcing market[59]. - The company reported a total of 973 new molecules in its pipeline, including 1 commercialized molecule, with a cumulative total of 2,341 molecules, comprising 50 commercial projects and 57 in clinical phase III[9]. Financial Management and Liabilities - The company's net cash flow from operating activities for 2022 was RMB 10,229.7 million, an increase of 133.6% compared to 2021, driven by rapid revenue growth and improved operational efficiency[29]. - The net cash used in investing activities for 2022 was RMB 9,311.2 million, up 101.2% from 2021, primarily due to increased capital expenditures for projects in various cities and investments in joint ventures[30]. - The total liabilities as of December 31, 2022, amounted to RMB 17,763.7 million, up from RMB 16,369.9 million in 2021, with 40.8% being accounts payable and other payables[31]. - The debt-to-asset ratio as of December 31, 2022, was 27.5%, down from 29.7% in 2021, reflecting an increase in retained earnings and net assets[34]. - The company has no significant contingent liabilities as of December 31, 2022[34]. Dividend and Shareholder Returns - The company proposed a final dividend of RMB 8.9266 per 10 shares, subject to shareholder approval[3]. - The board proposed a profit distribution plan for the year ending December 31, 2022, with a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 (including tax)[107]. - The proposed profit distribution plan for 2022 includes a total dividend payout of RMB 2,644,137,750.80, translating to a dividend of RMB 0.89266 per share, an increase from RMB 0.5174 per share in 2021[140]. Risks and Challenges - The company faces risks from potential declines in demand for pharmaceutical R&D services, which could negatively impact its business[92]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, as the company must adapt to evolving policies and regulations[93]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to enhance its R&D capabilities[94]. - The company is exposed to foreign exchange risk, particularly if the RMB appreciates significantly, which could increase costs and lead to a decrease in customer orders[99]. Corporate Governance - The board confirmed adherence to corporate governance codes, although there was a deviation regarding the separation of the roles of Chairman and CEO, which are currently held by the same individual[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements and internal controls for the reporting period[112].

Financial Performance - The company's revenue for Q3 2022 reached ¥10,638,303,791.29, representing a 77.76% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥2,742,164,675.92, a significant increase of 209.11% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥2,382,204,909.91, reflecting a 143.31% increase compared to the previous year[5] - The company's revenue for the first three quarters of 2022 reached RMB 28,394.56 million, representing a year-on-year growth of 71.9%[11] - The net profit attributable to shareholders for the current reporting period was RMB 2,091.1 million, with a year-to-date net profit of RMB 1,071.2 million, reflecting improved capacity utilization and operational efficiency[11] - Total revenue for the first three quarters of 2022 reached ¥28.39 billion, a significant increase of 72% compared to ¥16.52 billion in the same period of 2021[27] - Net profit attributable to shareholders for the first three quarters of 2022 was ¥7.38 billion, up 74% from ¥3.56 billion in the same period of 2021[28] - Operating profit for the first three quarters of 2022 was ¥8.84 billion, an increase of 105% compared to ¥4.30 billion in the same period of 2021[27] - The company reported a significant increase in contract liabilities, which rose to RMB 3,959,048,700.05 from RMB 2,986,378,875.46, reflecting a growth of about 32.5%[26] Earnings and Shareholder Returns - The basic earnings per share for the quarter was ¥0.93, an increase of 210.00% year-over-year[6] - The diluted earnings per share was ¥0.81, reflecting a 170.00% increase compared to the same period last year[6] - The diluted earnings per share for the current reporting period was RMB 1.70, up from RMB 0.90 in the same period last year[11] - Basic earnings per share for the first three quarters of 2022 were ¥2.52, up from ¥1.22 in the same period of 2021[28] - The adjusted profit attributable to shareholders of the parent company for Q3 2022 was CNY 2,742,165 thousand, compared to CNY 887,126 thousand in Q3 2021, marking a growth of around 208.5%[37] - The company paid dividends amounting to CNY 1,529,442 thousand in the first three quarters of 2022, compared to CNY 892,980 thousand in the same period of 2021, representing an increase of about 71.4%[36] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥7,709,650,548.49, which is a 142.38% increase year-over-year[5] - The cash flow from operating activities for the year-to-date period was RMB 14,238 million, indicating strong cash generation capabilities[11] - The net cash generated from operating activities for the first three quarters of 2022 was CNY 7,430,657 thousand, a significant increase from CNY 3,069,256 thousand in the same period of 2021, representing a growth of approximately 142.5%[35] - The company reported a net cash outflow from investing activities of ¥6.11 billion for the first three quarters of 2022, compared to a net outflow of ¥4.27 billion in the same period of 2021[29] - The company reported a net cash outflow from investing activities of CNY 5,846,717 thousand for the first three quarters of 2022, compared to CNY 4,161,234 thousand in the same period of 2021, indicating an increase in investment expenditures[35] - The company’s cash flow from financing activities showed a net outflow of CNY 688,415 thousand in the first three quarters of 2022, compared to a net outflow of CNY 1,601,146 thousand in the same period of 2021, reflecting an improvement in financing cash flow[36] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥65,749,216,761.50, which is a 19.27% increase from the end of the previous year[6] - As of September 30, 2022, the total assets of the company reached RMB 65,749,216,761.50, an increase from RMB 55,127,388,384.03 at the end of 2021, representing a growth of approximately 19.0%[25] - The company's current assets totaled RMB 25,455,729,627.61, up from RMB 21,985,648,602.33 in the previous year, indicating a year-over-year increase of about 15.4%[25] - The total liabilities of the company were RMB 20,612,129,366.80, up from RMB 16,369,925,768.22, representing an increase of around 26.5%[26] - The equity attributable to shareholders reached RMB 44,810,034,664.07, compared to RMB 38,491,509,630.60, indicating a growth of approximately 16.5%[26] - The company’s long-term liabilities decreased to CNY 3,138,273 thousand as of September 30, 2022, from CNY 3,385,332 thousand at the end of 2021, showing a decline of approximately 7.3%[34] Business Operations and Growth - The company had 45,646 employees, with 13,488 holding a master's degree or higher, and 1,379 holding a doctoral degree or equivalent[4] - The company operates 32 operational bases globally, serving over 5,900 active clients from more than 30 countries[4] - The number of new customers exceeded 1,000, with active customers surpassing 5,900, indicating strong demand for the company's services globally[10] - Revenue from U.S. customers was RMB 18,991 million, a 110% increase year-on-year, while revenue from Chinese customers grew by 30% to RMB 5,318 million[10] - The chemical business segment generated RMB 20,816.66 million in revenue, a 106.6% increase compared to the same period last year, driven by significant growth in process development and production services[11] - The testing business segment achieved revenue of RMB 4,177.08 million, reflecting a year-on-year growth of 25.3%, with laboratory analysis and testing services growing by 35.2%[13] - The company continues to implement a "long-tail customer" strategy, with significant growth in long-tail customer performance observed in the first three quarters of 2022[11] - The company announced plans for a new base in Singapore and commenced construction of a new production facility in Middletown, Delaware, to better meet global partner needs[12] Research and Development - Research and development expenses increased to ¥1.09 billion, up 69% from ¥644 million in the same period of 2021[27] - Research and development expenses for Q3 2022 were RMB 432,068 thousand, up from RMB 239,775 thousand in Q3 2021[31] - The biology segment (WuXi Biology) achieved revenue of RMB 1,779.38 million, a year-on-year increase of 24.9% compared to RMB 1,424.33 million in the same period of 2021[14] - The cell and gene therapy CTDMO business (WuXi ATU) reported revenue of RMB 921.65 million, up 25.2% from RMB 735.93 million in 2021, with testing business revenue growing by 44% and process development revenue increasing by 54%[15] - The domestic new drug development services unit (WuXi DDSU) generated revenue of RMB 671.80 million, a decline of 27.9% from RMB 931.80 million in the same period last year, primarily due to business upgrades to meet higher client demands[17] - The company completed 15 IND applications and received 26 clinical trial approvals in 2022, with a total of 159 IND applications and 136 clinical trial approvals by the end of Q3 2022[17] - The biology segment's revenue from new molecular types and biopharmaceuticals grew by 76% year-on-year, increasing its contribution to total biology revenue from 14.6% in 2021 to 20.5% in the first three quarters of 2022[14] - The company is currently working on 15 new molecular type preclinical projects, with several expected to submit IND applications by the end of 2022 or early 2023[17] - The company has 38 TESSA™ projects under client evaluation, including collaborations with six major biotech/pharmaceutical companies[16] - The TESSA™ technology, launched in March 2022, allows for the production of AAV at a scale of 200L, which is over ten times more efficient than traditional plasmid-based methods[15]

Financial Performance - The company's operating revenue for Q3 2022 reached approximately RMB 10.64 billion, representing a year-on-year increase of 77.76%[6] - Net profit attributable to shareholders for the same period was approximately RMB 2.74 billion, reflecting a significant increase of 209.11% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 2.38 billion, up 143.31% compared to the previous year[6] - The basic earnings per share for Q3 2022 was RMB 0.93, an increase of 210.00% year-on-year[6] - The diluted earnings per share was RMB 0.81, showing a year-on-year increase of 170.00%[6] - The company's operating revenue for the first three quarters of 2022 reached RMB 28,394.56 million, representing a year-on-year increase of 71.9%[13] - The net profit attributable to shareholders of the listed company for the current reporting period was RMB 2,091.10 million, with a year-to-date figure of RMB 1,071.20 million[8] - The company achieved a basic earnings per share of RMB 2.10 for the current reporting period, compared to RMB 1.07 for the year-to-date[9] - Total revenue for the first three quarters of 2022 reached ¥28,394,561,790.41, a significant increase of 72% compared to ¥16,521,369,391.37 in the same period of 2021[30] - Operating profit for the first three quarters of 2022 was ¥8,842,196,326.34, up from ¥4,302,311,952.74 in 2021, reflecting a growth of approximately 105.5%[30] - Net profit attributable to shareholders for the first three quarters of 2022 was ¥7,377,913,928.98, compared to ¥3,562,226,936.53 in 2021, indicating an increase of about 106%[31] Assets and Liabilities - The total assets attributable to shareholders reached approximately RMB 65.75 billion, a year-on-year increase of 19.27%[6] - The equity attributable to shareholders was approximately RMB 44.81 billion, reflecting a year-on-year increase of 16.42%[6] - Total liabilities as of September 30, 2022, amounted to ¥20,612,129,366.80, up from ¥16,369,925,768.22 at the end of 2021, representing a growth of approximately 26.5%[29] - The company's total equity reached ¥45,137,087,394.70 as of September 30, 2022, compared to ¥38,757,462,615.81 at the end of 2021, marking an increase of about 16.3%[29] - The company's total assets reached RMB 65,749,216,761.50 as of September 30, 2022, compared to RMB 55,127,388,384.03 at the end of 2021[27] - The company's total current liabilities increased to ¥17,473,856,415.48 as of September 30, 2022, from ¥12,984,593,869.40 in 2021, representing a growth of about 34.3%[28] Revenue Sources - Revenue from the chemical business (WuXi Chemistry) was RMB 20,816.66 million, up 106.6% from RMB 10,077.19 million in the same period last year[13] - Revenue from U.S. customers was RMB 18,991 million, a year-on-year increase of 110%[12] - Revenue from existing customers was RMB 27,546 million, reflecting an 80% year-on-year growth[12] - The company’s revenue from the top 20 global pharmaceutical companies was RMB 12,918 million, marking a 21% year-on-year increase[12] Customer and Workforce - The company served over 5,900 active clients from more than 30 countries as of the end of the reporting period[5] - The workforce comprised 45,646 employees, with 13,488 holding master's degrees or higher, and 1,379 holding doctoral degrees[5] - The company added over 1,000 new customers in the first three quarters of 2022, with active customer numbers exceeding 5,900[12] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥1,089,268,152.01, compared to ¥644,205,887.55 in 2021, reflecting a rise of approximately 69.2%[30] - The company’s CRDMO service revenue continues to grow rapidly, with a total of 2,123 new drug molecules involved in chemical business services as of Q3 2022, including 53 in Phase III, 288 in Phase II, and 1,738 in preclinical stages[14] - The number of customers for D&M services in the oligonucleotide and peptide drug sector reached 97, a year-on-year increase of 98%, with service revenue reaching RMB 1.1 billion, a year-on-year growth of 406%[14] Cash Flow and Investments - The company reported a net cash flow from operating activities of RMB 14,238 million for the year-to-date[9] - The net cash flow from operating activities for the first three quarters of 2022 was RMB 770,965.05 million, representing a year-on-year increase of 142%[20] - The company reported a net cash outflow from investing activities of RMB 5,846,717 thousand in the first three quarters of 2022, compared to RMB 4,161,234 thousand in the same period of 2021[41] - The company paid dividends totaling RMB 1,529,442 thousand in the first three quarters of 2022, an increase from RMB 892,980 thousand in the same period of 2021[42] Future Outlook and Plans - The company announced plans for a new base in Singapore and commenced construction of a new production base in Middletown, Delaware, to better meet global partner needs[14] - The company adjusted its full-year revenue growth target for 2022 from 68-72% to 70-72%, reflecting confidence in its CRDMO and CTDMO business models[20] - The company emphasizes that its 2022 performance outlook is based on current order status and various external factors, indicating significant uncertainty[20]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 17,756.3 million, representing a 68.5% increase from RMB 10,536.6 million in the same period of 2021[5] - Gross profit for the same period was RMB 6,426.8 million, up 65.5% from RMB 3,883.7 million year-on-year[5] - The net profit attributable to shareholders for the six months was RMB 4,635.7 million, a 73.3% increase from RMB 2,675.1 million in the prior year[5] - The overall gross profit for the first half of 2022 was RMB 6,426.8 million, a year-on-year increase of 65.5%, with a gross margin of 36.2%, down 0.7 percentage points from the previous year[22] - The company raised its full-year revenue growth target for 2022 from 65-70% to 68-72%, reflecting confidence in achieving strong growth[20] - Adjusted EBITDA for the six months ended June 30, 2022, was RMB 6,483.1 million, up from RMB 3,942.4 million in 2021, representing a growth of 64.5%[44] - The adjusted profit attributable to the parent company for the six months ended June 30, 2022, was RMB 4,635.7 million, compared to RMB 2,675.1 million in 2021, reflecting an increase of 73.1%[45] Customer Base and Revenue Sources - The number of active customers exceeded 5,850, with approximately 650 new active customers added during the reporting period[7] - Revenue from existing clients amounted to RMB 17,366 million, reflecting a year-on-year increase of 79%; revenue from new clients was RMB 391 million[9] - Revenue from US clients reached RMB 11,909 million, up 104% year-on-year; revenue from Chinese clients was RMB 3,175 million, an increase of 27%; revenue from European clients was RMB 1,853 million, growing by 24%[9] - The top 20 global pharmaceutical companies accounted for 44.2% of total revenue, a year-on-year increase of 165%[7] - Long-tail customers contributed 55.8% of total revenue, reflecting a 31% year-on-year growth[7] Segment Performance - WuXi Chemistry segment generated revenue of RMB 12,974.1 million, a 101.9% increase compared to RMB 6,425.8 million in the same period of 2021[11] - WuXi Testing segment reported revenue of RMB 2,605.0 million, up 23.6% from RMB 2,107.2 million year-on-year, with laboratory analysis and testing services growing by 34.6%[15] - WuXi Biology segment's revenue reached RMB 1,090.7 million, an 18.5% increase from RMB 920.2 million in the previous year[11] Assets and Liabilities - Total assets as of June 30, 2022, were RMB 61,913.5 million, a 12.3% increase from RMB 55,127.4 million at the end of 2021[5] - Total liabilities as of June 30, 2022, amounted to RMB 19,520.1 million, up from RMB 16,369.9 million as of December 31, 2021, with a debt-to-asset ratio of 31.5%[36] - The company's cash and cash equivalents decreased by 13.2% to RMB 7,094.2 million from RMB 8,175.3 million[5] Research and Development - R&D expenses grew from RMB 404.4 million to RMB 657.2 million, reflecting a year-on-year increase of 62.5%, as the company continued to invest heavily in R&D capabilities[29] - The company is actively developing new molecular types, with 15 preclinical projects initiated in the first half of 2022, including peptide-drug conjugates and protein degraders[19] - The company completed 9 IND submissions and obtained 19 clinical trial approvals in the first half of 2022, with a cumulative total of 153 IND submissions and 129 clinical trial approvals[19] Operational Efficiency and Investments - Cash generated from operating activities increased by 82.6% to RMB 3,767.9 million, driven by strong revenue growth and improved operational efficiency[33] - Cash used in investing activities rose by 51.7% to RMB 3,770.1 million, primarily due to increased capital expenditures for project construction[35] - The company plans to utilize cash flow from operations, bank loans, and funds raised from convertible bonds and new shares to meet operational and investment needs[42] Financial Risks and Management - The company faced foreign exchange risks due to transactions in multiple currencies, impacting its financial performance[42] - The company reported a significant increase in income tax expenses, rising 77.4% to RMB 865.2 million, attributed to higher taxable profits from subsidiaries[32] - The company has established a robust internal control system to ensure compliance with relevant laws and regulations, although risks remain due to the number of subsidiaries[99][100] Shareholder and Equity Management - A total of 5,916,743 restricted A-shares were released from restrictions, accounting for approximately 0.2001% of the company's total issued share capital at that time[72] - The company approved the repurchase of 4,517 restricted A-shares at a price of RMB 18.17 per share due to the departure of three incentive targets before the lock-up period expired[136] - The company has not conducted any fundraising activities during the reporting period[132] Strategic Initiatives and Future Plans - The company aims to enhance its drug development service platform to meet diverse customer needs and capitalize on the rapid growth of the global drug development outsourcing market[59] - The company plans to invest in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapies to seize new business opportunities[60] - The company is exploring cutting-edge technologies like AI and big data to improve drug development efficiency and reduce barriers[61] Employee Incentives and Management - The company is committed to attracting and retaining top talent through performance-based incentives, training opportunities, and competitive compensation packages[93] - The company has implemented various employee incentive plans since 2015, including stock option plans for different employee categories[172] - The total number of shares granted under the 2015 stock option incentive plan was 16,200,000, with an exercise price of RMB 8.00[173]